Beaware of this stock which is listed in SGX and KLSE. These are cronies political stock which was owned by our one timed former PM Mathier. The crossed border listing of stocks on both side of SGX and KLSE was closed by former PM Dr. Mathier due to the financial crisis in 1997. Backgorund...who control Parkmay the forerunner of IHH? Whom was Vincent Tan of Berjaya Group whom has recently stepped down are the runner for Big Boss....Who is the Big Boss whose office is registerd in Bangsar, K.L. Please do some reflection.
Eventhough IHH is a little political shares I supposed, but I am thinking this is better than Genting SP for the moment. Better buy uptrending shares than to buy a downtrend shares. Just my 2 cents opinion. Huat ahhhh...
Aha, Now CIMB are more decent. 1.53 is logic, but like the Average Target Price 2.22...... Well, Long term IHH will definitely create value for its shareholders. The journey have just begin....
Grossly overvalued stock. If politics is a factor, price should be artificially inflated come election but know when to get out or u will be left holding an overweight baby for a long long time. Hope dividend will make up for it then. Good luck to all invested.
They are two healthcare stock listed SGX, is good for long term under ur portfolio. Raffles medical small but growing slowly , compare PE, IHH is highest.
IHH Healthcare may be threatened by a decline in Indonesian patients
HEALTHCARE | Staff Reporter, Singapore Published: 2 hours 57 min ago
According to CIMB, it thinks that since only 18% of total patients admitted to PPL Singapore come from Indonesia, the net contribution from this group is only about 3% of the group’s PATMI, considering (i) domestic patients’revenue intensity has increase sharply, (ii) more than half of the cases from Indonesian patients are non-elective treatments and (iii) larger contributions from other markets dilute its sensitivity to this risk.
Here's more from CIMB:
2Q13 and 1H13 core earnings were in line, accounting for 22% and 37% of our FY13 numbers. However, we cut FY13-15 estimates by 7-9% as we see more start-up and other opex costsgoing forward.
Our SOP-based target price is reduced as a result. We keep our Outperform rating as we expect a more robust ramp-up of the group’s global operations.
Marked improvement 2Q13 core net profit was driven by growth at its new hospitals, savings in finance costs and the recapitalisation of Acibadem. This offset the depreciation and finance costsrelating to new hospitals that had to be recognised in the P&L after completion.
There was a one-off RM22m tax credit in 2Q13 relating to the tax reversal in Singapore.
There was a marked improvement in the average revenue per inpatient at all of its hospitals in Singapore, Malaysia and Turkey. Excluding the accounting treatment for REIT, all of its business segments recorded revenue growth both yoy and sequentially.
Novena, as predicted, broke even on an EBITDA level in 2Q13. We expect an EBITDA breakeven point for Acibadem Bodrum sometime in 4Q13.
Healthcare provider IHH Healthcare Berhad (SGX: Q0F) slipped by 5.4% to S$1.48. Its second quarter results were also released yesterday evening and they aren’t pretty. Quarterly revenue declined by 38% year-on-year to RM1.68b while profits sank 61% to RM157m. SGX Stock Picks | Singapore Stock Recommendations | Best Shares to Buy @ (http://goo.gl/chE0k2)
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
Report Abuse
Please Sign In to report this post as abuse.
Market Buzz
No result.
Featured Posts
MQ Chat
New Update. Discover investment communities that resonate with your ideas
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
edcheong
1 posts
Posted by edcheong > 2012-07-26 14:44 | Report Abuse
A stock to add to your portfolio in these bad times.